
|Articles|May 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 5
- Volume 17
- Issue 5
First trial of RXR agonist
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.
Advertisement
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.
Articles in this issue
over 18 years ago
Immunotherapy agent promising in NSCLCover 18 years ago
NCCN greenlights nilotinib for imatinib-resistant CML patientsover 18 years ago
No overall survival benefit for dose-intense regimen in SCLCover 18 years ago
Make a note of new smoking cessation codesover 18 years ago
Relistor for treating OICover 18 years ago
Experts argue against need for phase III proton Rx trialsover 18 years ago
Spotlight on Cancer Centersover 18 years ago
Novel peptide vaccine promising in myeloid leukemiaover 18 years ago
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALLAdvertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Gastric Cancers
2
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
3
Lenvatinib Combo Holds Ground Against HER2 ADCs in Endometrial Cancer
4
FDA Grants Fast Track Designation to ERAS-0015 for Pancreatic Adenocarcinoma
5






























































